67,803 Shares in Novavax, Inc. (NASDAQ:NVAX) Bought by XTX Topco Ltd

Key Points

• XTX Topco Ltd has acquired 67,803 shares of Novavax, Inc. (NASDAQ: NVAX), valued at approximately $435,000, according to its recent 13F filing.
• Novavax recently reported earnings of $0.62 per share, exceeding estimates, with revenue of $239.24 million during the quarter.
• Institutional investors currently hold 53.04% of Novavax's stock, reflecting significant interest from hedge funds and investment firms.

XTX Topco Ltd acquired a new stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 67,803 shares of the biopharmaceutical company's stock, valued at approximately $435,000.

Several other institutional investors have also bought and sold shares of the business. Federated Hermes Inc. lifted its position in Novavax by 11.1% during the first quarter. Federated Hermes Inc. now owns 56,124 shares of the biopharmaceutical company's stock valued at $360,000 after purchasing an additional 5,618 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Novavax in the first quarter valued at $71,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Novavax in the first quarter valued at $99,000. Hussman Strategic Advisors Inc. raised its stake in shares of Novavax by 100.0% in the first quarter. Hussman Strategic Advisors Inc. now owns 168,000 shares of the biopharmaceutical company's stock valued at $1,077,000 after acquiring an additional 84,000 shares during the period. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Novavax in the first quarter valued at $290,000. Institutional investors own 53.04% of the company's stock.

Wall Street Analyst Weigh In

NVAX has been the topic of several recent analyst reports. Bank of America reduced their target price on shares of Novavax from $10.00 to $9.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 22nd. B. Riley reissued a "buy" rating on shares of Novavax in a research note on Monday, May 19th. JPMorgan Chase & Co. dropped their target price on shares of Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a research note on Friday, May 9th. Finally, Citigroup assumed coverage on shares of Novavax in a research note on Tuesday, June 17th. They issued a "sell" rating and a $6.00 target price on the stock. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Novavax has a consensus rating of "Hold" and a consensus price target of $15.86.

Novavax Stock Up 5.1%

NASDAQ NVAX traded up $0.41 during trading on Tuesday, reaching $8.44. 5,401,600 shares of the company's stock traded hands, compared to its average volume of 6,613,721. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 3.70, a price-to-earnings-growth ratio of 0.10 and a beta of 2.50. The company's 50 day simple moving average is $7.00 and its two-hundred day simple moving average is $7.17. Novavax, Inc. has a 12-month low of $5.01 and a 12-month high of $15.22.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.69. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The business had revenue of $239.24 million for the quarter, compared to analysts' expectations of $149.19 million. During the same period last year, the business earned $0.99 EPS. The company's revenue was down 42.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.